NCT00907166View on ClinicalTrials.gov

A Phase I/II Open-Label Dose-Escalation Clinical Trial of CPI-613 in Combination With Gemcitabine in Cancer Patients

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

May 31, 2009

Primary Completion Date

December 31, 2017

Study Completion Date

December 31, 2017

Conditions
CancerPancreatic CancerPancreatic Carcinoma
Interventions
DRUG

CPI-613

IV infusion of CPI-613 given on Days 1,4, 8, 11, 15, 18, of 28 day cycle in cancer patients.

DRUG

CPI-613

IV infusion of CPI-613 given on Days 1, 4, 8, 11, 15, 18, of 28 day cycle in patients with pancreatic carcinoma.

DRUG

Gemcitabine

IV infusion of 1000 mg/m\^2 of Gemcitabine given on Days 1, 8, and 15 of a 28 day cycle in patients with pancreatic carcinoma.

DRUG

Gemcitabine

IV infusion of 1000 mg/m\^2 of Gemcitabine given on Days 1, 8, and 15 of a 28 day cycle in cancer patients.

DRUG

Gemcitabine

IV infusion of 1000 mg/m\^2 of Gemcitabine given on Days 1, 8, and 15 of a 28 day cycle in patients with pancreatic carcinoma.

Trial Locations (2)

10469

Eastchester Center for Cancer Care, The Bronx

75201

Mary Crowley Cancer Research Centers, Dallas

Sponsors
All Listed Sponsors
lead

Cornerstone Pharmaceuticals

INDUSTRY

NCT00907166 - A Phase I/II Open-Label Dose-Escalation Clinical Trial of CPI-613 in Combination With Gemcitabine in Cancer Patients | Biotech Hunter | Biotech Hunter